We’re proud to be joining and sponsoring @EWhiteheadFdn’s #BelieveBall in Philadelphia tonight! We’re looking forward to a night of celebrating the courage of patients and their families and supporting a brighter future with #AdvancedTherapies: hubs.ly/Q04yl5t-0
1
14
There are moments when the connection between the work we do & the people it can ultimately help serve as a powerful reminder of why #ItsPersonal. For Dr. Noah, one of those moments was supporting urgent research needs during the #COVID19 pandemic: hubs.ly/Q04xYl_B0
17
Don't miss Estephan's session on "Beyond the Biopsy: Combining In Vitro #LiverModels, #LiquidBiopsy and #NAMS to Study Liver Transplant Rejection" on Thursday, October 1st at the Congresso Português de Transplantação in Coimbra, Portugal: hubs.ly/Q04yfv9d0
1
24
Join us for a webinar on advancing #MetabolicDisease #DrugDevelopment featuring different models & studies to address specific questions, including a comparison of #GLP1 #DrugMetabolism with different test systems. Learn more and register: hubs.ly/Q04xYkNq0
1
34
BioIVT supports the R&D continuum from discovery to clinical translation as a single-source #biospecimens provider with extensive, diverse, high-quality tissue, biofluid & cells featuring robust online & direct ordering capabilities: hubs.ly/Q04x_9j-0
See an example ⬇️
20
Our team is ready at #Biomarkers, #CDx & #PrecisionMedicine booth #8 to discuss how we can support your research with high quality, extensively characterized biospecimens representing both normal and extensive disease indications!
1
23
Our experts are getting ready for the #ISSX2026 North American Meeting – we’ll be presenting on a number of different topics and will be available at booth #504 to discuss all things #ADME: hubs.ly/Q04xY9R-0
#DMPK #DrugMetabolism #PeptideDrugs #MASLD
1
14
With CYP enzymes responsible for most #DrugMetabolism, the #ICHM12 guideline requires evaluation of CYP1A2, CYP2B6 & CYP3A4 induction. But when should #CYP2C induction also be considered? hubs.ly/Q04xY8vB0
#ADME #DrugInteractions #DrugDevelopment #RegulatoryCompliance
1
25
Our experts will be available to discuss your #ADME questions at the 2026 DMDG-GMP-SPS Joint Meeting! Dr. Barbara will be presenting a poster on lysosomal catabolism of #peptidedrugs. Learn more & schedule a meeting with the team: hubs.ly/Q04xY6pc0
#GLP1 #DrugMetabolism
1
30
Drug-induced liver injury (#DILI) is a major cause of drug attrition. A new mechanism-based human in vitro approach provides additional insight into bile acid-induced #hepatotoxic potential during #preclinical assessment. Explore the study: hubs.ly/Q04xDVsm0
#Toxicity
1
31
In #PlasmaProteomics analytical platforms are only part of the equation. Disease severity, underlying pathophysiology & cohort size/diversity can greatly impact proteomic signals.
Explore the data for insights on selecting cohorts for plasma proteomics: hubs.ly/Q04xnztY0
17
Our team is ready to help you source biospecimens at #MASH #DrugDevelopment Summit booth #5. Don’t miss Dr. Ogilvie presenting "Beyond the Liver: Integrating Human Adipose and Hepatic Models to Strengthen Translational Confidence in MASH Drug Development" at 12:10pm on Thursday!
2
31
Mike Walden and Ryan King are at #CARTCRSummit booth #23 in #Boston! Stop by to discuss overcoming the challenge of accessing reliable, high-quality, fit-for-purpose cellular starting materials.
#CARTcell #CellTherapy #Oncology #Autoimmune
25
#Autoimmune, inflammatory, and allergic diseases are highly heterogeneous. Selecting biospecimens with the right biological and clinical context can account for variability to result in more relevant, reproducible studies. Learn more: hubs.ly/Q04xnsVY0
1
23
Our September New Resources Newsletter is now available and features updates, insights and information on a variety of topics including #NAMs, #biomarkers & #multiomics, #transdermal #skinresearch, #liverdisease models, and more: hubs.ly/Q04xysqQ0
1
14
A skin model is only as useful as the insights it can provide. Explore different options, where ex vivo skin can add value, and the key factors researchers should consider when planning a study: hubs.ly/Q04xm1Cr0
#Transdermal #SkinResearch
1
14
Vienna waits for you... and so does BioIVT at #EUROTOX2026!
Visit Booth #32 to meet our team and explore #ADME-Tox solutions supporting #drugdevelopment and view our e-poster LP-71 on a new mechanism-based human in vitro screen for cholestatic #DILI.
#Toxicity #Toxicology #DMPK
1
23
Dr. Warren didn’t intentionally set out to build a 30-year career around #DrugTransporters. In his #MeetTheExpert blog, Mark shares how a classically trained biochemist expecting to pursue protein engineering found himself drawn into transporter research: hubs.ly/Q04wWrnl0
1
29
Donor selection for #CellandGeneTherapy goes beyond demographics. Immune cell composition, HLA type, KIR genotype and other factors can determine downstream application performance.
Watch the full webinar: hubs.ly/Q04wWmrh0
#CellTherapy #CGT #AdvancedTherapies #ATMPs
26
BioIVT helps researchers build #GLP1 and #MetabolicDisease studies around the right donors. Access normal and disease-state biospecimens across type 2 diabetes, obesity/BMI categories, and more, with customizable cohorts based on key donor characteristics: hubs.ly/Q04wWbs30
1
26